FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246823268> ?p ?o ?g. }

• W4246823268 abstract "Background Clostridium difficile (C. difficile) is recognized as a frequent cause of antibiotic‐associated diarrhea and colitis. Objectives The aim of this review is to establish the efficacy of antibiotic therapy for C. difficile‐associated diarrhea (CDAD), to identify the most effective antibiotic treatment for CDAD in adults and to determine the need for stopping the causative antibiotic during therapy. Search methods MEDLINE (1966 to 2003), EMBASE (1980 to 2003), Cochrane Central Database of Controlled Trials and the Cochrane IBD Review Group Specialized Trials Register were searched using the following search terms: pseudomembranous colitis and randomized trial; Clostridium difficile and randomized trial; antibiotic associated diarrhea and randomized trial. Selection criteria Only randomized, controlled trials assessing antibiotic treatment for CDAD were included in the review. Probiotic trials are excluded. The following outcomes were sought: initial resolution of diarrhea; initial conversion of stool to C. difficile cytotoxin and/or stool culture negative; recurrence of diarrhea; recurrence of fecal C. difficile cytotoxin and/or positive stool culture; patient response to cessation of prior antibiotic therapy; sepsis; emergent surgery: fecal diversion or colectomy; and death. Data collection and analysis Data were analyzed using the MetaView statistical package in Review Manager. For dichotomous outcomes, relative risks (RR) and 95% confidence intervals (CI) were derived from each study. When appropriate, the results of included studies were combined for each outcome. For dichotomous outcomes, pooled RR and 95% CI were calculated using a fixed effect model, except where significant heterogeneity was detected, at which time the random effects model was used. Data heterogeneity was calculated using MetaView. Main results Of eleven studies identified, two were subsequently excluded because patients were stool positive for C. difficile, but did not have diarrhea or because the study was not a randomized controlled trial. All of the remaining nine studies involved patients with diarrhea who recently received antibiotics for an infection other than C. difficile. The definition of diarrhea ranged from at least two loose stools per day with an associated symptom such as rectal temperature > 38oC, to at least six loose stools in 36 hours. In terms of symptomatic cure, metronidazole, bacitracin and fusidic acid were not shown to be less effective than vancomycin. Teicoplanin may be slightly more effective than vancomycin with a relative risk of 1.21 [95% CI 1.00 to 1.46] and a p‐value of 0.06. In terms of initial symptomatic resolution, vancomycin is more effective than placebo with a relative risk of 6.75 [95% CI 1.16 to 48.43] and a p‐value of 0.03. This result should be interpreted with caution given the small number of patients in this comparison (12 in the vancomycin group and nine in the placebo group) and the poor methodological quality of the trial. Metronidazole, bacitracin, teicoplanin, fusidic acid and rifaximine are as effective as vancomycin for initial symptomatic resolution. The other secondary outcomes measured in this review: surgery, sepsis and death occurred infrequently in all of the studies. Authors' conclusions Current evidence leads to uncertainty whether mild CDAD needs to be treated. Patients with mild CDAD may resolve their symptoms as quickly without treatment. The only placebo‐controlled study shows vancomycin's superior efficacy. However, this result should be treated with caution due to the small number of patients enrolled and the poor methodological quality of the trial. The Johnson study of asymptomatic carriers also shows that placebo is better than vancomycin or metronidazole for eliminating C. difficile in stool during follow‐up. If one does decide to treat, then two goals of therapy need to be kept in mind: improvement of the patient's clinical condition and prevention of spread of C. difficile infection to other patients. Given these two considerations, one should choose the antibiotic that brings both symptomatic cure and bacteriologic cure. In this regard, teicoplanin appears to be the best choice because the available evidence suggests that it is better than vancomycin for bacteriologic cure and has borderline superior effectiveness in terms of symptomatic cure. Teicoplanin is not readily available in the United States, which must be taken into account when making treatment decisions in that country." @default.
• W4246823268 created "2022-05-12" @default.
• W4246823268 creator A5004179871 @default.
• W4246823268 creator A5006288469 @default.
• W4246823268 creator A5011936197 @default.
• W4246823268 creator A5069742942 @default.
• W4246823268 creator A5073906482 @default.
• W4246823268 creator A5078130634 @default.
• W4246823268 date "2005-01-24" @default.
• W4246823268 modified "2023-10-14" @default.
• W4246823268 title "Antibiotic treatment for Clostridium difficile-associated diarrhea in adults" @default.
• W4246823268 cites W1700100541 @default.
• W4246823268 cites W1706992259 @default.
• W4246823268 cites W1821236203 @default.
• W4246823268 cites W1966022325 @default.
• W4246823268 cites W1969791292 @default.
• W4246823268 cites W1985064297 @default.
• W4246823268 cites W1989355067 @default.
• W4246823268 cites W1992375749 @default.
• W4246823268 cites W1994090985 @default.
• W4246823268 cites W2011392840 @default.
• W4246823268 cites W2065280991 @default.
• W4246823268 cites W2066547211 @default.
• W4246823268 cites W2070342870 @default.
• W4246823268 cites W2122546651 @default.
• W4246823268 cites W2123831499 @default.
• W4246823268 cites W2124167692 @default.
• W4246823268 cites W2130150046 @default.
• W4246823268 cites W2152531094 @default.
• W4246823268 cites W2277430674 @default.
• W4246823268 cites W2318911370 @default.
• W4246823268 cites W2588112065 @default.
• W4246823268 cites W4206318298 @default.
• W4246823268 cites W4210578910 @default.
• W4246823268 cites W4211184309 @default.
• W4246823268 cites W4232577926 @default.
• W4246823268 cites W4253522366 @default.
• W4246823268 doi "https://doi.org/10.1002/14651858.cd004610.pub2" @default.
• W4246823268 hasPublicationYear "2005" @default.
• W4246823268 type Work @default.
• W4246823268 citedByCount "27" @default.
• W4246823268 countsByYear W42468232682012 @default.
• W4246823268 countsByYear W42468232682013 @default.
• W4246823268 countsByYear W42468232682015 @default.
• W4246823268 countsByYear W42468232682017 @default.
• W4246823268 crossrefType "reference-entry" @default.
• W4246823268 hasAuthorship W4246823268A5004179871 @default.
• W4246823268 hasAuthorship W4246823268A5006288469 @default.
• W4246823268 hasAuthorship W4246823268A5011936197 @default.
• W4246823268 hasAuthorship W4246823268A5069742942 @default.
• W4246823268 hasAuthorship W4246823268A5073906482 @default.
• W4246823268 hasAuthorship W4246823268A5078130634 @default.
• W4246823268 hasConcept C126322002 @default.
• W4246823268 hasConcept C168563851 @default.
• W4246823268 hasConcept C177713679 @default.
• W4246823268 hasConcept C2776258884 @default.
• W4246823268 hasConcept C2776478404 @default.
• W4246823268 hasConcept C2776667177 @default.
• W4246823268 hasConcept C2779134260 @default.
• W4246823268 hasConcept C2779802037 @default.
• W4246823268 hasConcept C2779915187 @default.
• W4246823268 hasConcept C2780479503 @default.
• W4246823268 hasConcept C2991793726 @default.
• W4246823268 hasConcept C2994496256 @default.
• W4246823268 hasConcept C44249647 @default.
• W4246823268 hasConcept C501593827 @default.
• W4246823268 hasConcept C71924100 @default.
• W4246823268 hasConcept C82789193 @default.
• W4246823268 hasConcept C86803240 @default.
• W4246823268 hasConcept C89423630 @default.
• W4246823268 hasConceptScore W4246823268C126322002 @default.
• W4246823268 hasConceptScore W4246823268C168563851 @default.
• W4246823268 hasConceptScore W4246823268C177713679 @default.
• W4246823268 hasConceptScore W4246823268C2776258884 @default.
• W4246823268 hasConceptScore W4246823268C2776478404 @default.
• W4246823268 hasConceptScore W4246823268C2776667177 @default.
• W4246823268 hasConceptScore W4246823268C2779134260 @default.
• W4246823268 hasConceptScore W4246823268C2779802037 @default.
• W4246823268 hasConceptScore W4246823268C2779915187 @default.
• W4246823268 hasConceptScore W4246823268C2780479503 @default.
• W4246823268 hasConceptScore W4246823268C2991793726 @default.
• W4246823268 hasConceptScore W4246823268C2994496256 @default.
• W4246823268 hasConceptScore W4246823268C44249647 @default.
• W4246823268 hasConceptScore W4246823268C501593827 @default.
• W4246823268 hasConceptScore W4246823268C71924100 @default.
• W4246823268 hasConceptScore W4246823268C82789193 @default.
• W4246823268 hasConceptScore W4246823268C86803240 @default.
• W4246823268 hasConceptScore W4246823268C89423630 @default.
• W4246823268 hasLocation W42468232681 @default.
• W4246823268 hasOpenAccess W4246823268 @default.
• W4246823268 hasPrimaryLocation W42468232681 @default.
• W4246823268 hasRelatedWork W1520771971 @default.
• W4246823268 hasRelatedWork W1984572269 @default.
• W4246823268 hasRelatedWork W200570179 @default.
• W4246823268 hasRelatedWork W2064557171 @default.
• W4246823268 hasRelatedWork W2135137912 @default.
• W4246823268 hasRelatedWork W2404266303 @default.
• W4246823268 hasRelatedWork W2404950116 @default.
• W4246823268 hasRelatedWork W2417025048 @default.
• W4246823268 hasRelatedWork W2423693600 @default.

• next